NORWALK, Conn.--(BUSINESS WIRE)--An increasing number of type 2 diabetes patients in the U.S. are being treated by a progressively complex mix of therapies, according to a study featured in Archives of Internal Medicine, a JAMA/Archives journal. The report is the first to be published by members of the Health Services Research Network (HSRN), a consortium of leading U.S. academicians that conducts independent research using IMS Health’s evidence-based information to address key healthcare issues. IMS Health (NYSE: RX) is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries.
